CEO: Sheila Gujrathi

Headquarters: San Diego

Funding: $276 million IPO, preceded by $330 million in two funding rounds

Stock symbol and listing: GOSS on NASDAQ

Company Description: Gossamer has a six-drug pipeline that ranges from oncology to asthma to inflammatory bowel disease.

Two analyst teams who recently started covering Gossamer Bio see a promising future for the San Diego biotech...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129